The important Long COVID findings, distilled. Understand the headline numbers, what they mean for the people studied, and where the picture is still developing.
INSIDE THIS MONITOR
42cited sources
99available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY38%lower relative odds
Unresolved Long COVID was linked to work disruption
Compared with no or short-duration symptoms, unresolved Long COVID was associated with 38% lower relative odds of paid work and higher odds of changing working hours.
Adults in an English population-based cohort were followed for a median of 23 months; approximately 4% had unresolved Long COVID. These adjusted associations do not establish that Long COVID caused the employment changes.
See the evidence
38% lower relative odds, calculated from aOR 0.62. This is not an absolute percentage-point difference.
Odds of being in paid work at follow-up among participants with unresolved Long COVID versus those with no or short-duration symptoms
aOR 0.62 95% CI: 0.55-0.70
Di Gravio, Chiara et al.. Long COVID symptom profiles, workforce participation, and working hours among adults in England: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Odds of changing working hours among participants with unresolved Long COVID versus those with no or short-duration symptoms
aOR 4.34 95% CI: 3.88-4.85
Di Gravio, Chiara et al.. Long COVID symptom profiles, workforce participation, and working hours among adults in England: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Prevalence of unresolved Long COVID at follow-up; median follow-up was 23 months
Approximately 4% (1,967/45,864)
Di Gravio, Chiara et al.. Long COVID symptom profiles, workforce participation, and working hours among adults in England: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Many reached baseline symptoms, but recovery varied
92% at 24 months (Kaplan-Meier estimate)
The cohort estimated that 92% reached symptom levels at or below pre-infection baseline by 24 months; the median time was 226 days. More symptoms were associated with slower recovery.
Participants had post-COVID-19 condition, and recovery meant symptom decline to pre-infection baseline. This endpoint and population-based cohort should not be generalized to everyone with Long COVID.
See the evidence
Symptom decline to pre-infection baseline or below among people with PCC
92% at 24 months (Kaplan-Meier estimate)
Brunet, Jean-Patrick L et al.. Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Time to symptom decline to pre-infection baseline among people with PCC
Median 226 days (IQR 182-372); most improvement within the first 235 days
Brunet, Jean-Patrick L et al.. Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Likelihood of recovery, defined as symptom decline to pre-infection baseline, with each additional symptom
HR 0.69 per additional symptom 95% CI: 0.63-0.76
Brunet, Jean-Patrick L et al.. Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study.. The Lancet regional health. Europe. 2026.
A systematic review pooled brain fog at 30% and cognitive impairment at 25% among people with Long COVID.
The estimates concern Long COVID populations included in the review. Detailed definitions, study designs, and follow-up periods are not available in this summary, limiting applicability across settings.
See the evidence
Pooled prevalence of brain fog in long COVID populations
30% 95% CI: 28-32
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Pooled prevalence of cognitive impairment in long COVID populations
25% 95% CI: 23-27
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Depression and anxiety risks were higher at 3 years
86%higher relative risk
At 3 years after infection, adults with Long COVID had 86% higher relative risk of depressive symptoms and 60% higher relative risk of anxiety symptoms than adults without Long COVID.
These were prospective population-based associations with nearly three-year follow-up. The comparison does not establish that Long COVID caused the mental-health symptoms.
See the evidence
86% higher relative risk, calculated from aRR 1.86. This is not an absolute percentage-point difference.
Depressive symptoms at 3 years post-infection in adults with Long COVID vs. without
aRR 1.86 95% CI: 1.34-2.57
Ryu, Soomin et al.. Prospective associations between Long COVID and mental health: evidence from a population-based study with a nearly three-year follow-up.. BMC public health. 2026.
Anxiety symptoms at 3 years post-infection in adults with Long COVID vs. without
aRR 1.60 95% CI: 1.18-2.16
Ryu, Soomin et al.. Prospective associations between Long COVID and mental health: evidence from a population-based study with a nearly three-year follow-up.. BMC public health. 2026.
A southeastern Brazil study associated reinfection with higher odds of Long COVID. The RECOVER-Adult cohort separately associated reinfection with a higher hazard.
The findings came from infected people in southeastern Brazil and an adult RECOVER cohort. Study designs and reference-group details are not available in this summary, so causality and absolute risk are uncertain.
See the evidence
One reinfection increased long COVID risk
OR 2.35 95% CI 1.84-3.01
Barboza, Ana Paula Bandeira et al.. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.. Vaccine. 2026.
Two or more reinfections further increased long COVID risk
OR 4.22 95% CI 2.043-7.91
Barboza, Ana Paula Bandeira et al.. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.. Vaccine. 2026.
Prevention signals exist, but evidence is not uniform
Acute nirmatrelvir/ritonavir use was associated with lower Long COVID odds. A second booster also showed lower odds than a primary series. Pediatric onset showed no clear difference for at least one dose versus no vaccination.
An outpatient meta-analysis provided the antiviral result; its comparator is not available in this summary. During Omicron in southeastern Brazil, a second booster was compared with a primary series. The pediatric review compared at least one dose with no vaccination. Absolute risks and safety outcomes are not available in this summary.
See the evidence
Reduced likelihood of developing post-COVID-19 condition with nirmatrelvir/ritonavir use during acute infection
OR 0.85 95% CI: 0.80-0.91
Cucunawangsih, Cucunawangsih et al.. Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. 2026.
During Omicron period, second booster dose reduced long COVID risk by 50% versus primary series
OR 0.50 95% CI 0.34-0.74
Barboza, Ana Paula Bandeira et al.. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.. Vaccine. 2026.
No statistically significant difference in pediatric Long-COVID onset between individuals with at least one anti-SARS-CoV-2 vaccine dose and unvaccinated individuals.
OR 0.92 95% CI: 0.61-1.41
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Having at least 7 acute-phase symptoms was associated with higher Long COVID odds. Immunosuppressant therapy was associated with lower odds in analyses stratified by follow-up time.
This retrospective cohort involved discharged patients with Omicron infection in Changzhi. The reference groups for these associations are not available in this summary, and the therapy finding does not establish prevention.
Study details & original results
Yang, Jianzhou et al.. Risk factors of long COVID among discharged patients with omicron infection in Changzhi, China: a retrospective cohort study.. Frontiers in public health. 2026.
Association between having at least 7 acute-phase symptoms and long COVID in analyses stratified by follow-up time
OR 1.275 95% CI: 1.064-1.528
Association between immunosuppressant therapy and lower long COVID odds in analyses stratified by follow-up time
Hospitalized-cohort patterns changed across epidemic periods
40.2% (252/627)
Long COVID was reported in 40.2% of this cohort. Observed risk fell from above 50% in the Wild-type/Alpha period to below 21% in the Delta/Omicron period, while fatigue increased after admission.
This was a retrospective cohort of hospitalized survivors. The period comparison was observational and did not isolate a causal effect of viral variant.
Study details & original results
Daodu, Lanre Peter et al.. Phenotypic Evolution, Clinical Subtypes, and Independent Predictors of Long COVID: A Retrospective Cohort Study.. Biomedicines. 2026.
Prevalence of long COVID among adults hospitalized with acute COVID-19 in this cohort
40.2% (252/627)
Observed long-COVID risk declined from the Wild-type/Alpha period to the Delta/Omicron period among hospitalized survivors
>50% to <21%
Systemic fatigue increased approximately fourfold from admission to post-acute follow-up
Neurologic symptoms were frequent through 36 months
53%-65%
Across serial assessments, fatigue was reported by 53%-65%, memory or concentration difficulty by 47%-61%, and sleep disturbance by 40%-48%.
Participants had been hospitalized for COVID-19 and were assessed through 36 months. The ranges span different assessments and should not be generalized to all infected people.
Study details & original results
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Fatigue prevalence across serial assessments through 36 months after COVID-19 hospitalization
53%-65%
Memory/concentration difficulty prevalence across serial assessments through 36 months after COVID-19 hospitalization
47%-61%
Sleep-disturbance prevalence across serial assessments through 36 months after COVID-19 hospitalization
Higher wellbeing correlated with lower Long COVID odds
23%lower relative odds
Europeans aged 50 years or older in the highest psychological wellbeing group had 23% lower relative odds of Long COVID than those in the lowest group.
This was an observational association in the SHARE study. It does not show that improving psychological wellbeing would prevent Long COVID.
Study details & original results
Gao, Yumeng et al.. Association between psychological wellbeing and the COVID-19-related outcomes in Europeans aged ≥ 50 years old: The SHARE study.. Human vaccines & immunotherapeutics. 2026.
Odds of long COVID among adults aged 50 years or older in the highest versus lowest CASP-12 psychological wellbeing score group
OR 0.77 95% CI: 0.64-0.93
23% lower relative odds, calculated from OR 0.77. This is not an absolute percentage-point difference.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 99 findingsOriginal results, comparisons and study details.
23 of 23 source groupsFindings stay together with their study.
SOURCE 423 findings
Yang, Jianzhou et al.. Risk factors of long COVID among discharged patients with omicron infection in Changzhi, China: a retrospective cohort study.. Frontiers in public health. 2026.
Daodu, Lanre Peter et al.. Phenotypic Evolution, Clinical Subtypes, and Independent Predictors of Long COVID: A Retrospective Cohort Study.. Biomedicines. 2026.
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Gao, Yumeng et al.. Association between psychological wellbeing and the COVID-19-related outcomes in Europeans aged ≥ 50 years old: The SHARE study.. Human vaccines & immunotherapeutics. 2026.
Brunet, Jean-Patrick L et al.. Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Time to symptom decline to pre-infection baseline among people with PCC
Added
Median 226 days (IQR 182-372); most improvement within the first 235 daysSource [38]
SOURCE 367 findings
Alshomrani, Abdulaziz et al.. Determinants and Consequences of Long Impact of COVID-19: A National Cross-Sectional Study in Saudi Arabia.. Journal of clinical medicine. 2026.
Yang, Jianzhou et al.. Longitudinal trajectories of long COVID among hospitalized patients with omicron infection in Changzhi, China.. Frontiers in medicine. 2026.
Papantoniou, Kyriaki et al.. Night work, sleep disruption and long-COVID risk: a population-based cohort study.. Scandinavian journal of work, environment & health. 2026.
Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.
No significant difference in the composite multi-domain deficit score between long COVID cases and controls after adjustment for age, sex, ethnicity, cohort membership, and relatedness
Added
Adjusted mean difference 0.22 units95% CI: -0.44-0.88Source [32]
Multivariable-adjusted odds of a vascular-domain deficit in long COVID cases versus controls, largely attributable to elevated blood pressure
Multivariable-adjusted odds of a vascular-domain deficit when long COVID cases were restricted to those reporting fatigue, largely attributable to elevated blood pressure
Di Gravio, Chiara et al.. Long COVID symptom profiles, workforce participation, and working hours among adults in England: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Sõnajalg, Hanna et al.. Bidirectional associations between chronic diseases and Long COVID: a population-based cohort and interrupted time-series analysis.. Frontiers in public health. 2026.
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Pooled prevalence of Long COVID among children and adolescents; estimates varied according to the diagnostic criteria used.
Added
18.1% (16.2% using NIH criteria; 21.6% using WHO criteria)95% CI: 13.1-23.6 for the overall pooled estimateSource [30]
No statistically significant difference in pediatric Long-COVID onset between individuals with at least one anti-SARS-CoV-2 vaccine dose and unvaccinated individuals.
Castro, Victor M et al.. Characterization and Validation of EHR Computable Phenotypes for Long COVID Using Patient-Reported Symptoms: Insights from the Nationwide RECOVER Program.. Journal of the American Medical Informatics Association : JAMIA. 2026.
Mikdashi, Fatima et al.. Estimating the Quality-Adjusted Life-Year Loss due to Fatal and Nonfatal COVID-19 Outcomes across US States and Counties, July 2020 to December 2022.. MDM policy & practice. 2026.
Estimated annual US quality-adjusted life-year loss attributable to Long COVID
Added
Approximately 865,000 QALYs lost annually95% UI: 355,000-1,591,000Source [28]
SOURCE 271 finding
Zhang, Yue et al.. Association between dietary inflammatory index, empirical dietary inflammatory patterns and the risk of Long COVID: a prospective cohort study.. BMC public health. 2026.
Bruschi, Mario et al.. Prevalence of long covid symptoms in Tuscany, Italy: a population-representative cross-sectional telephone survey.. BMJ open. 2026.
Barboza, Ana Paula Bandeira et al.. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.. Vaccine. 2026.
Ryu, Soomin et al.. Prospective associations between Long COVID and mental health: evidence from a population-based study with a nearly three-year follow-up.. BMC public health. 2026.
Cucunawangsih, Cucunawangsih et al.. Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. 2026.
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Jason LA, Islam MF, Conroy K, et al. COVID-19 symptoms over time: Comparing long-haulers to ME/CFS. Fatigue: Biomedicine, Health & Behavior. 2023;11(2):104-118.
Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21(3):133-146.
Komaroff AL, Lipkin WI. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends in Molecular Medicine. 2021;27(9):895-906.
Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany. Nature Communications. 2022;13:5104.
Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens. BMJ. 2006;333(7568):575.
Raj SR, Arnold AC, Barboi A, et al. Long-COVID postural tachycardia syndrome: an American Autonomic Society statement. Clinical Autonomic Research. 2021;31:365-368.
Chen C, Haupert SR, Zimmermann L, et al. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. Journal of Infectious Diseases. 2022;226(9):1593-1607.
Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. The Lancet. 2022;400(10350):452-461.
Bruschi, Mario et al.. Prevalence of long covid symptoms in Tuscany, Italy: a population-representative cross-sectional telephone survey.. BMJ open. 2026.
Barboza, Ana Paula Bandeira et al.. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil.. Vaccine. 2026.
Ryu, Soomin et al.. Prospective associations between Long COVID and mental health: evidence from a population-based study with a nearly three-year follow-up.. BMC public health. 2026.
Cucunawangsih, Cucunawangsih et al.. Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis.. Expert review of anti-infective therapy. 2026.
Lawal, Bukola et al.. Post-acute metabolic changes and risk of new-onset diabetes following COVID-19: a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Faseeh, Ahmar et al.. Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review.. Medicine. 2026.
Zhang, Yue et al.. Association between dietary inflammatory index, empirical dietary inflammatory patterns and the risk of Long COVID: a prospective cohort study.. BMC public health. 2026.
Mikdashi, Fatima et al.. Estimating the Quality-Adjusted Life-Year Loss due to Fatal and Nonfatal COVID-19 Outcomes across US States and Counties, July 2020 to December 2022.. MDM policy & practice. 2026.
Castro, Victor M et al.. Characterization and Validation of EHR Computable Phenotypes for Long COVID Using Patient-Reported Symptoms: Insights from the Nationwide RECOVER Program.. Journal of the American Medical Informatics Association : JAMIA. 2026.
Cioni, Giovanni et al.. The Burden of Long-COVID-19 Among Pediatric Subjects: A Systematic Review and Meta-Analysis.. Journal of clinical medicine. 2026.
Sõnajalg, Hanna et al.. Bidirectional associations between chronic diseases and Long COVID: a population-based cohort and interrupted time-series analysis.. Frontiers in public health. 2026.
Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.
Di Gravio, Chiara et al.. Long COVID symptom profiles, workforce participation, and working hours among adults in England: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Papantoniou, Kyriaki et al.. Night work, sleep disruption and long-COVID risk: a population-based cohort study.. Scandinavian journal of work, environment & health. 2026.
Yang, Jianzhou et al.. Longitudinal trajectories of long COVID among hospitalized patients with omicron infection in Changzhi, China.. Frontiers in medicine. 2026.
Alshomrani, Abdulaziz et al.. Determinants and Consequences of Long Impact of COVID-19: A National Cross-Sectional Study in Saudi Arabia.. Journal of clinical medicine. 2026.
Brunet, Jean-Patrick L et al.. Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study.. The Lancet regional health. Europe. 2026.
Gao, Yumeng et al.. Association between psychological wellbeing and the COVID-19-related outcomes in Europeans aged ≥ 50 years old: The SHARE study.. Human vaccines & immunotherapeutics. 2026.
Lee, Eunyoung A et al.. Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19.. Frontiers in neurology. 2026.
Daodu, Lanre Peter et al.. Phenotypic Evolution, Clinical Subtypes, and Independent Predictors of Long COVID: A Retrospective Cohort Study.. Biomedicines. 2026.
Yang, Jianzhou et al.. Risk factors of long COVID among discharged patients with omicron infection in Changzhi, China: a retrospective cohort study.. Frontiers in public health. 2026.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.